Wellness Clinical Research — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$2,827	1
2024	Research	$69,515	10
2023	Research	$61,610	8
2022	Research	$194,084	10
2021	Research	$214,686	14
2020	Research	$71,758	12
2019	Research	$1,500	1

Breakdown

Who paid Research payments · program years 2019–2025

AstraZeneca Pharmaceuticals LP $279,304 22 payments
Merck Sharp & Dohme Corporation $145,374 2 payments
Pfizer Inc. $133,397 19 payments
Amgen Inc. $21,353 3 payments
E.R. Squibb & Sons, L.L.C. $21,038 3 payments
GlaxoSmithKline, LLC. $12,970 5 payments
Vifor (International) Ltd. $2,444 1 payment
AbbVie, Inc. $101 1 payment

Studies the money was for Research payments · program years 2019–2025

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Concomitant Administration of Either 23-Valent Pneumococcal Polysaccharide Vaccine or 15-Valent Pneumococcal Conjugate Vaccine with a Booster Dose of SARS-CoV-2 mRNA Vaccine in Healthy Adults 50 Years of Age or Older. $143,874 1 payment
A Phase 3 Randomized Doubleblind Trial to Evaluate the Safety and Immunogenicity of A 20Valent Pneumococcal Conjugate Vaccine 20Vpnc When Coadministered With Seasonal Inactivated Influenza Vaccine Siiv in Adults 65 Years of Age $119,628 9 payments
A 54 Week Treatment, Multicenter, Randomized, Double Blind, Double Dummy, Placebo and Active Controlled, Parallel Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis $113,560 5 payments
A Phase 2 Open-label, Long-term Extension Safety Study of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis $78,298 5 payments
This study seeks to evaluate the safety and efficacy of brazikumab versus placebo (Stage I) and versus an active comparator (Stage 2) in participants with moderately to severely active CD and will include assessments of clinical response as demonstrated by improvement of symptoms and colonic mucosal appearance as observed on endoscopy $49,016 7 payments
An Open label Long term Extension Study of Brazikumab in Participants with Moderately to Severely Active Crohns Disease $38,430 5 payments
CORE Ph3 Prurigo Nodularis #1 $18,526 2 payments
A Phase 4, Global, Prospective, Open label Study of Ozanimod to Explore the Safety, Efficacy, Quality of Life, and Biomarker Response in Participants with Moderate to Severe Ulcerative Colitis in Clinical Practice $11,064 1 payment
A Phase 3 Randomized Doubleblind 52Week Placebocontrolled Multicenter Study With A Doubleblind 52Week Extension Period With Randomized Dose Updose Down Titration Investigating the Efficacy Safety and Tolerability of Ritlecitinib in Adult Participants With Nonsegmental Vitiligo $9,997 6 payments
Study name not reported $9,970 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.